The company remains in a pre-revenue stage with operating losses widening to $27.3 million in 2026Q1, driven by a significant increase in R&D expenditure from $7.2 million in 2023Q4.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 1.21M | 850K | 380K | 45K | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | -1.21M | -850K | -380K | -45K | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | 100% | -42% | -123.68% | -744.44% | - | - |
| Operating Expenses | 93.04M | 84.04M | 58.02M | 44.65M | 32.83M | 15.61M | 119.02M | 74.96M | 45.86M | 18.34M | 4.63M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 21.71M | 20.55M | 16.65M | 7.68M | 7.18M | 4.63M | 32.99M | 19.98M | 10.77M | 3.15M | 1.96M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 71.32M | 63.49M | 41.36M | 36.97M | 25.65M | 10.98M | 86.03M | 54.97M | 35.09M | 15.19M | 2.66M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -93.04M | -84.04M | -58.02M | -44.65M | -32.83M | -15.61M | -120.23M | -75.81M | -46.24M | -18.39M | -4.63M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -44.85% | -29.94% | -36% | -110.31% | 87.02% | -58.59% | -63.94% | -151.51% | -297.54% | - |
| EBITDA | -89.14M | -82.66M | -56.37M | -43.17M | -31.82M | -15.25M | -119.02M | -74.96M | -45.86M | -18.34M | -4.66M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -44.42% | -46.64% | -30.58% | -35.65% | -108.74% | 87.19% | -58.78% | -63.44% | -150.06% | -293.25% | - |
| D&A (Non-Cash Add-back) | 1.03M | 1.38M | 1.65M | 1.48M | 1.01M | 364K | 1.21M | 850K | 380K | 45K | 0 |
| EBIT | -84.27M | -72.86M | -57.88M | -42.67M | -32.04M | -8.48M | -119.71M | -72.97M | -46.36M | -18.65M | -4.66M |
| Net Interest Income | 10.98M | 11.23M | 4.15M | 429K | 5K | -224K | 719K | 2.93M | 0 | 0 | 0 |
| Interest Income | 11.03M | 11.3M | 4.26M | 581K | 149K | 0 | 719K | 2.93M | 1.73M | 57K | 6K |
| Interest Expense | 51K | 63K | 107K | 152K | 144K | 224K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 10.78M | 11.12M | 33K | 1.82M | 650K | 6.68M | 516K | 2.84M | -118K | -262K | -39K |
| Pretax Income | -82.26M | -72.92M | -57.98M | -42.82M | -32.18M | -8.93M | -119.71M | -72.97M | -46.36M | -18.65M | -4.66M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 1.23M | 1.23M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -1.5% | -1.69% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -83.49M | -74.15M | -57.98M | -42.82M | -32.18M | -8.93M | -119.71M | -72.97M | -46.36M | -18.65M | -4.66M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -42.3% | -27.89% | -35.4% | -33.07% | -260.48% | 92.54% | -64.07% | -57.38% | -148.61% | -299.83% | - |
| Net Income (Continuing) | -83.49M | -74.15M | -57.98M | -42.82M | -32.18M | -8.93M | -119.71M | -72.97M | -46.36M | -18.65M | -4.66M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.45 | -4.05 | -3.93 | -11.53 | -29.05 | -33.36 | -39.68 | -31.92 | -23.41 | -9.35 | -2.34 |
| EPS Growth % | 38.99% | -3.05% | 65.92% | 60.31% | 12.92% | 15.93% | -24.31% | -36.35% | -150.37% | -299.57% | - |
| EPS (Basic) | - | -4.05 | -3.93 | -11.59 | -29.05 | -33.36 | -39.68 | -31.92 | -23.41 | -9.35 | -2.34 |
| Diluted Shares Outstanding | 18.77M | 18.32M | 14.77M | 3.71M | 3.64M | 3.57M | 3.02M | 2.29M | 1.98M | 1.99M | 1.99M |
| Basic Shares Outstanding | 18.77M | 18.32M | 14.77M | 3.69M | 3.64M | 3.57M | 3.02M | 2.29M | 1.98M | 1.99M | 1.99M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - |
Clinical trial execution failure
As reported in recent financial statements, Tectonic Therapeutic's R&D expenses reached $20.9 million in 2026Q1, reflecting a clear upward trajectory in clinical development spending compared to the $7.2 million recorded in 2023Q4 as the company advances its GEODe platform and lead RXFP1 agonist program.
The consistent rise in R&D spending suggests an intensification of clinical trial activities and the associated costs of specialized protein engineering. Investors should monitor whether this expense growth remains proportional to the clinical milestones achieved or if it indicates potential inefficiencies in managing complex biologic development pipelines.
Based on the company's reported figures, operating losses have widened to $27.3 million in 2026Q1, demonstrating that the firm's current operational structure is entirely dependent on external capital rather than internal revenue generation to support its ongoing research and administrative overhead requirements.
The lack of revenue means that operating leverage is currently non-existent, as every dollar of increased R&D or SG&A directly expands the net loss. This structure implies that the company's valuation will remain highly sensitive to the timing of clinical readouts rather than traditional operational efficiency metrics.
According to quarterly filings, stock-based compensation has become a recurring line item, reaching $5.1 million in 2025Q4, which warrants further investigation into the potential for shareholder dilution as the company scales its headcount to support the expansion of its clinical-stage pipeline.
While stock-based compensation is a standard tool for talent retention in biotechnology, its increasing magnitude relative to the total operating loss suggests that equity-based incentives are a significant component of the company's cost structure. Investors should assess whether this compensation aligns with long-term value creation or merely reflects the high cost of specialized labor.
As indicated by the quarterly burn rate, which reached $27.3 million in 2026Q1, the company's reliance on its $253.8 million cash position suggests that future capital raises may be necessary if clinical timelines for the RXFP1 program extend beyond current management projections.
The primary risk to the current narrative is that the high cash burn rate may force dilutive financing before the company can demonstrate meaningful clinical efficacy. Market participants should be wary of the potential for valuation compression if the company's cash runway is perceived to be insufficient for reaching critical Phase 2 milestones.
Quick answers to the most common questions about buying TECX stock.
For fiscal year 2025, Tectonic Therapeutic, Inc. (TECX) reported total revenue of $0.0M.
Tectonic Therapeutic, Inc. (TECX) reported a net loss of $74.2M for the fiscal year ending 2025.